Adcetris brentuximab vedotin: Interim Phase II data

Interim data from 22 evaluable patients with high-intermediate and high-risk DLBCL in an open-label, U.S. Phase II trial showed that 1.2 or 1.8 mg/kg IV Adcetris every 3 weeks for up to 6 cycles plus R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment led to an ORR of 95%, including 17 complete remissions and 4 partial remissions. Seattle Genetics said preliminary data suggest a higher complete remission rate in CD30-positive patients vs. CD30-undetectable DLBCL patients. Across both treatment arms, 100% of patients achieved tumor reduction. Data were presented at the American Society of Hematology meeting in San Francisco. Seattle Genetics plans to add a cohort of CD30-positive DLBCL patients to receive first-line treatment with Adcetris plus R-CHOP chemotherapy without vincristine. ...